Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices

Emiko Petrosky, Joseph A Bocchini Jr, Susan Hariri, Harrell Chesson, C Robinette Curtis, Mona Saraiya, Elizabeth R Unger, Lauri E Markowitz, Centers for Disease Control and Prevention (CDC), Emiko Petrosky, Joseph A Bocchini Jr, Susan Hariri, Harrell Chesson, C Robinette Curtis, Mona Saraiya, Elizabeth R Unger, Lauri E Markowitz, Centers for Disease Control and Prevention (CDC)

Abstract

During its February 2015 meeting, the Advisory Committee on Immunization Practices (ACIP) recommended 9-valent human papillomavirus (HPV) vaccine (9vHPV) (Gardasil 9, Merck and Co., Inc.) as one of three HPV vaccines that can be used for routine vaccination. HPV vaccine is recommended for routine vaccination at age 11 or 12 years. ACIP also recommends vaccination for females aged 13 through 26 years and males aged 13 through 21 years not vaccinated previously. Vaccination is also recommended through age 26 years for men who have sex with men and for immunocompromised persons (including those with HIV infection) if not vaccinated previously. 9vHPV is a noninfectious, virus-like particle (VLP) vaccine. Similar to quadrivalent HPV vaccine (4vHPV), 9vHPV contains HPV 6, 11, 16, and 18 VLPs. In addition, 9vHPV contains HPV 31, 33, 45, 52, and 58 VLPs. 9vHPV was approved by the Food and Drug Administration (FDA) on December 10, 2014, for use in females aged 9 through 26 years and males aged 9 through 15 years. For these recommendations, ACIP reviewed additional data on 9vHPV in males aged 16 through 26 years. 9vHPV and 4vHPV are licensed for use in females and males. Bivalent HPV vaccine (2vHPV), which contains HPV 16, 18 VLPs, is licensed for use in females. This report summarizes evidence considered by ACIP in recommending 9vHPV as one of three HPV vaccines that can be used for vaccination and provides recommendations for vaccine use.

References

    1. Markowitz LE, Dunne EF, Saraiya M, et al. Centers for Disease Control and Prevention (CDC) Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2014;63(RR-05):1–30.
    1. Food and Drug Administration. Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant) Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. Highlights of prescribing information. Available at .
    1. Food and Drug Administration. December 10, 2014 Approval letter—GARDASIL 9. Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2014. Available at .
    1. Luxembourg A. Program summary and new 9-valent HPV vaccine trial data. Presentation before the Advisory Committee on Immunization Practices (ACIP); October 30, 2014; Atlanta, GA: US Department of Health and Human Services, CDC; 2014. Available at .
    1. Ahmed F, Temte JL, Campos-Outcalt D, Schünemann HJ ACIP Evidence Based Recommendations Work Group (EBRWG) Methods for developing evidence-based recommendations by the Advisory Committee on Immunization Practices (ACIP) of the US Centers for Disease Control and Prevention (CDC) Vaccine. 2011;29:9171–6.
    1. CDC. GRADE evidence tables—recommendations in MMWR. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at .
    1. Muñoz N, Bosch FX, de Sanjosé S, et al. International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.
    1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B: a review of human carcinogens. IARC Monographs Eval Carcinog Risks Hum. 2012;100(Pt B):1–441.
    1. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999;189:12–9.
    1. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(Suppl 5):F12–23.
    1. Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer. 2012;7:38.
    1. Saraiya M. Population-based HPV genotype attribution in HPV-associated cancers. Presented at Anal Intraepithelial Neoplasia Society Conference; March 13–15, 2015; Atlanta, GA.
    1. CDC. Human papillomavirus (HPV)-associated cancers. Atlanta, GA: US Department of Health and Human Services, CDC; 2015. Available at .
    1. Hariri S, Unger ER, Schafer S, et al. HPV-IMPACT Working Group. HPV type attribution in high-grade cervical lesions: assessing the potential benefits of vaccines in a population-based evaluation in the United States. Cancer Epidemiol Biomarkers Prev. 2015;24:393–9.
    1. Lacey CJ, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine. 2006;24(Suppl 3):35–41.
    1. Joura EA, Giuliano AR, Iversen OE, et al. Broad Spectrum HPV Vaccine Study. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372:711–23.
    1. Brisson M. Cost-effectiveness of 9-valent HPV vaccination. Presentation before the Advisory Committee on Immunization Practices (ACIP); October 30, 2014; Atlanta, GA: US Department of Health and Human Services, CDC; 2014. Available at .
    1. Food and Drug Administration. Cervarix [human papillomavirus bivalent (types 16, 18) vaccine, recombinant] Silver Spring, MD: US Department of Health and Human Services, Food and Drug Administration; 2009. Highlights of prescribing information. Available at .
    1. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16:175–204.
    1. Moyer VA, editor. US Preventive Services Task Force. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;156:880–91. W312.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner